Leerink upgraded the stock after AbbVie announced it was acquiring Allergan and said it expects the company to get "even more" synergies.

"Based on AbbVie's new dividend yield of 6.5%, the sustainability and likely growth of that dividend through 2023 (at least) and the high probability that AbbVie will extract even more synergies from Allergan than was suggested yesterday, we are upgrading AbbVie to Outperform and maintaining our recent $88 target price for the stock."